Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 356-362

  He, Xu ^a,b   Andersson, Göran ^c   Lindgren, Urban ^a   Li, Yan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Basic Medical College   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Osteclasts; Reactive oxygen species (ROS); Resveratrol; Sirt1

Indexed keywords

FULVESTRANT; OSTEOCLAST DIFFERENTIATION FACTOR; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARBAZOLES; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVATION; MICE; OSTEOCLASTS; RANK LIGAND; REACTIVE OXYGEN SPECIES; SIRTUIN 1; STILBENES;

MURINAE;

EID: 77958153014     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.053     Document Type: Article

References (36)

1. Pirola L., Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 2008, 60:323-332.
2. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2000, 46:78-83.
3. Liu Z.P., Li W.X., Yu B., Huang J., Sun J., Huo J.S., Liu C.X. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J. Med. Food 2005, 8:14-19.
4. Habold C., Momken I., Ouadi A., Bekaert V., Brasse D. Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension. J. Nutr. Sci. Vitaminol. (Tokyo) 2000, 46:78-83.
5. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., De Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
6. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 1998, 253:859-863.
7. Su J.L., Yang C.Y., Zhao M., Kuo M.L., Yen M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J. Biol. Chem. 2007, 282:19385-19398.
8. Backesjo C.M., Li Y., Lindgren U., Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 2006, 21:993-1002.
9. Naruse M., Otsuka E., Ishihara Y., Miyagawa-Tomita S., Hagiwara H. Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells. Biochem. Pharmacol. 2004, 67:119-127.
10. Voronov I., Heersche J.N., Casper R.F., Tenenbaum H.C., Manolson M.F. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration. Biochem. Pharmacol. 2005, 70:300-307.
11. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005, 65:9943-9952.
12. Gabbay K.H., Bohren K.M., Morello R., Bertin T., Liu J., Vogel P. The ascorbate synthesis pathway: dual role of ascorbate in bone homeostasis. J. Biol. Chem. 2010, 285:19510-19520.
13. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
14. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
15. Wei S., Teitelbaum S.L., Wang M.W., Ross F.P. Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 2001, 142:1290-1295.
16. Reid I.R. Anti-resorptive therapies for osteoporosis. Semin. Cell Dev. Biol. 2008, 19:473-478.
17. Michels G., Watjen W., Weber N., Niering P., Chovolou Y., Kampkotter A., Proksch P., Kahl R. Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Toxicology 2006, 225:173-182.
18. Galal N., El-Beialy W.R., Deyama Y., Yoshimura Y., Suzuki K., Totsuka Y. Novel effect of estrogen on RANK and c-fms expression in RAW 264.7 cells. Int. J. Mol. Med. 2007, 20:97-101.
19. Lee N.K., Choi Y.G., Baik J.Y., Han S.Y., Jeong D.W., Bae Y.S., Kim N., Lee S.Y. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005, 106:852-859.
20. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. 2006, 72:1439-1452.
21. Trivedi R., Goswami R., Chattopadhyay N. Investigational anabolic therapies for osteoporosis. Expert Opin. Investig. Drugs 2010, 19:995-1005.
22. Renaud S., De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
23. Puel C., Coxam V., Davicco M.J. Mediterranean diet and osteoporosis prevention. Med. Sci. (Paris) 2007, 23:756-760.
24. Williams L.D., Burdock G.A., Edwards J.A., Beck M., Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol. 2009, 47:2170-2182.
25. Almeida L., Vaz-da-Silva M., Falcao A., Soares E., Costa R., Loureiro A.I., Fernandes-Lopes C., Rocha J.F., Nunes T., Wright L., Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53(Suppl. 1):S7-S15.
26. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
27. Li Y., Backesjo C.M., Haldosen L.A., Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur. J. Pharmacol. 2009, 609:13-18.
28. Solomon J.M., Pasupuleti R., Xu L., McDonagh T., Curtis R., DiStefano P.S., Huber L.J. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell Biol. 2006, 26:28-38.
29. Gehm B.D., McAndrews J.M., Chien P.Y., Jameson J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 1997, 94:14138-14143.
30. Shevde N.K., Bendixen A.C., Dienger K.M., Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 2000, 97:7829-7834.
31. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51:3867-3873.
32. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87:905-931.
33. Srinivasan S., Koenigstein A., Joseph J., Sun L., Kalyanaraman B., Zaidi M., Avadhani N.G. Role of mitochondrial reactive oxygen species in osteoclast differentiation. Ann. NY Acad. Sci. 2010, 1192:245-252.
34. Kim M.S., Yang Y.M., Son A., Tian Y.S., Lee S.I., Kang S.W., Muallem S., Shin D.M. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J. Biol. Chem. 2010, 285:6913-6921.
35. Rubiolo J.A., Mithieux G., Vega F.V. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 2008, 591:66-72.
36. Shin S.M., Cho I.J., Kim S.G. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol. Pharmacol. 2009, 76:884-895.